Catalogue

Background
Ibuprofen is an anti-inflammatory drug used for pain relief, fever reduction and against swelling. It is one of the most sold over-the-counter drugs. It is found in the environment, especially in the water environment in the vicinity of large cities and hospitals.

Source
Rabbit immune serum

Immunogen: BSA-Ibuprofen derivative conjugate

Product
Each vial contains 0.5 ml 0,8mg/ml of purified (caprylic acid) polyclonal antibody containing 0.02% sodium azide.

Specificity
Target: Ibuprofen, CAS no.: 15687-27-1, Solubility: Organic solvents, PEGs.

Species Reactivity: The specificity of the antibody was determined by measuring the cross-reactivity in ELISA for a range of compounds. Cross Reactivity Compound tested % Cross- reactivity Ibuprofen 100% Bezafibrate 0.4% Gemfibrozil 0.2% Bisphenol A 0.6% Carazolol <0.1% Metoprolol 0.1% Chlorpyrifos 0.3% Naproxen 2.2% Clofibrinic acid 0.3% Nonylphenol 1.3% Diclofenac <0.1% Octylphenol 0.6% Erythromycine 0.1% Propanolol 0.1% Fenitrothion 0.5% Vinclozolin <0.1% Fenofibrate 0.5% Zearalenon 0.2%

Applications
The antibody may be used in ELISA and Immuno-affinity-chromatography (IAC). Suggested dilution 1:300 in ELISA (this titer is defined as the dilution that gives 50 % of the absorbance from the maximum absorbance when tested with ELISA). Plates are coated with 400 ng/ml ovalbumine-conjugated derivative. HRP-conjugated anti-rabbit IgG should be used as a tracer in a 1:8,000 dilution.

Storage
Store at 4 °C or -20 °C. The working antibody solution is stable for at least 7 days at 4 °C. Precautions should be taken for storage for longer periods. Problems of longterm stability may occur with highly diluted solutions. For lng storage purposes in solution the addition of sodium azide to 0.02 % is advised with the appropriate precautions of use.

Shipping Conditions: Ship at ambient temperature.

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Derksen JGM, van Eijnatten GM, Lahr J, van der Linde P, Kroon AGM. (2000) Enviromental effects of human pharmaceuticals, p. 225, RIWA Report 2000.051, Lelystad, The Netherlands. 2. Meulenberg EP, Peelen GOH, Lukkien E, Koopal K. (2005) Immunochemical detection methods for bioactive pollutants. Intern. J. Environ. Anal. Chem. 85, 861-870